Management tracks: Curis, Gemphire

Cancer company Curis Inc. (NASDAQ:CRIS) named COO James Dentzer president and CEO and appointed him as a board member. He replaces Ali Fattaey, who is departing. Curis had promoted Dentzer to COO this year.

Cardiometabolic disorders company Gemphire Therapeutics Inc. (NASDAQ:GEMP) reduced headcount by five (about 33%) following FDA’s recent request for more preclinical data for gemcabene (CI-1027). The cuts comprise CFO Jeffrey Mathiesen, CMO Lee Golden and three other employees. Gemphire designated President and CEO Steven Gullans as principal financial officer and principal accounting officer...